AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
Anna Fink

Anna Fink

Universität zu Köln - Köln / Germany
Medical and Health Sciences / Hematology
AD Scientific Index ID: 5109117
University of Cologne
person_outline Anna Fink's MOST POPULAR ARTICLES
1-) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial The Lancet 376 (9747), 1164-1174, 2010
2-) Mutations driving CLL and their evolution in progression and relapse Nature 526 (7574), 525-530, 2015
3-) Venetoclax and obinutuzumab in patients with CLL and coexisting conditions New England Journal of Medicine 380 (23), 2225-2236, 2019
4-) Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial Blood, the Journal of the American Society of Hematology 127 (2), 208-215, 2016
5-) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10 … The lancet oncology 17 (7), 928-942, 2016